Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb study of GZR4 versus insulin icodec in adults with type 2 diabetes previously treated with basal insulin
CTR20253485Phase 3Active
- Sponsor
- Gannex Pharma Co., Ltd.
- Start
- Oct 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of GZR4 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Gannex Pharma Co., Ltd. Primary endpoint: Change from baseline in glycated hemoglobin. Started Oct 2025; status: active.
02
Drugs
GZR4
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20253485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253485.